Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-12-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于公司高管辞职的公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. regarding the resignation of a senior executive, specifically the Chief Operating Officer. It details the resignation date, shareholding information, and compliance with relevant regulations on share transfer restrictions post-resignation. There is no financial data, report, or presentation content. The document fits the category of announcing changes in senior management.
2018-12-28 Chinese
关于公司实际控制人、部分董事及控股股东核心管理团队增持公司股份计划的进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the progress of a share increase plan by the company's actual controller, some directors, and the core management team of the controlling shareholder. It details the amount of shares purchased, the price limits, the timeline, and the purpose of the share increase. It includes specific data on shareholding before and after the increase and confirms compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement about insider share purchases and progress updates on a shareholding plan. This fits best under the category of Transaction in Own Shares (POS), which covers reports of the company or insiders buying back or increasing their own shares. The document length is 3156 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is POS with high confidence.
2018-12-26 Chinese
关于控股股东部分股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the company's controlling shareholder. It details the number of shares pledged, the pledge period, the pledgee, and the proportion of shares pledged. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a shareholder's capital/financing activity (share pledge). It is not a full financial report or an announcement of a report. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short but contains substantive information about financing activity, not just a notice or report publication announcement.
2018-12-24 Chinese
第二届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Shenzhen BGI Genomics Co., Ltd. It details the meeting date, attendance, voting results, and decisions regarding capital investments and related party transactions. The content focuses on board meeting decisions and related disclosures rather than financial results, audit opinions, or regulatory certifications. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2018-12-21 Chinese
第二届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the second Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It details the meeting's convening, attendance, and voting results on investment and related party transactions. The content focuses on board-level decisions and approvals rather than financial results, audit opinions, or shareholder voting outcomes. It does not contain financial statements or earnings data, nor is it a report or presentation. The document is best classified as Board/Management Information (MANG) because it announces decisions made by the company's supervisory board regarding corporate governance matters and related party transactions.
2018-12-21 Chinese
中信证券股份有限公司关于公司以可转股债权方式对外投资暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities Co., Ltd. regarding an external investment by Shenzhen BGI Genomics Co., Ltd. through convertible debt and related party transactions. It includes comprehensive information about the investment agreement, parties involved, financial data, risk analysis, board and independent directors' opinions, supervisory board review, and the sponsor's verification opinion. The document references regulatory compliance with Shenzhen Stock Exchange rules and includes formal approvals and opinions from various company bodies. It is not a brief announcement or a simple notification but a thorough verification and opinion report on a specific investment transaction and related party dealings. This fits the definition of an Audit Report / Information (AR), as it is a standalone audit/verification report on a specific transaction, including applied regulations and internal approvals, rather than a full annual report or a simple announcement. The document length (12,679 characters) and content depth support this classification with high confidence. FY 2018
2018-12-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.